INTRODUCTION

Oral cancer along with pharyngeal cancer is regarded as the sixth most common cancer in the world with an increased incidence tagged to developing countries. \(^1\) In India, oral cancer ranks as the most prevalent cancer in men\(^2\) and the third most common cancer after cervical and breast cancer among women.\(^3\) The age-standardized incidence rate of oral cancer in India accounts to 12.6/100,000 people. This high incidence of oral cancer in India has been attached to high exposure to sunlight due to farming, smoking, smokeless tobacco habits, alcohol, spicy food, neglected overall oral health and human papilloma virus.\(^3,4\) The incidence of oral cancer appears to be increasing in several parts of the world, particularly in countries such as Australia, Japan and parts of Europe. Thus, oral cancer projects as a significant “Global burden.”\(^5\)

Malignancy may be defined as a neoplastic growth with potency to metastasize. The devastating aspects of cancer are attributed to the formation of metastatic foci. Occult metastatic tumor cells may become obscure and remain in a dormant state for longer duration following the resection or elimination of the primary tumor and then be activated by a stimulus leading to the formation of metastatic foci, which may promote mortality among patients.\(^5,6\) Oral cancers metastasize in regional lymph nodes before
actually metastasizing to distant sites, and this ability of regional lymph node metastasis is regarded as the factor that governs and influences the “Disease Survival Rate” in patients with oral squamous cell carcinoma (OSCC).\[7\]

The good lymphatic drainage from oral cavity and invasive potential acquired (cell motility factor) by malignant cells of OSCC establishes effective possibilities of regional lymph node metastasis. This establishment occurs through collective contribution of factors responsible for degradation of basement membranes, extracellular matrix (ECM) and action of matrix metalloproteinases (MMPs). The motility of cancer cells in tumor environment is brought by cleavage of ECM and thereby helps the propagation of tumor cells into the adjacent spaces. Therefore, cell motility, a prerequisite for a tumor cell for invasion, is under a coordinated balance between the cell adhesion receptors and the ECM. At present, the role of extracellular matrix or neomatrix in tumor development and progression is well established as ECM plays a vital role in cell adhesion, migration, proliferation, differentiation and gene expression.

Further, there exists also studies which have explored ECM components such as collagen\[8\] and laminin\[9‑11\] which are known to be abnormally increased and abnormally lost, respectively, in cancer. Therefore, a complete understanding of ECM or neomatrix role in OSCC becomes necessary to aid in the identification of new biomarkers for early prediction of OSCC that relies on components of the ECM, which may facilitate newer strategies for more effective therapy against oral cancers.

**METASTATIC CASCADE**

The metastatic cascade follows a sequential step which involves single tumor cell or groups of tumor cells to dissociate from the primary tumor, invade the surrounding ECM, including both basement membranes and interstitial compartments, enter the vascular or lymphatic space, escape immune surveillance and mechanical disruption, arrest at a distant site, escape from the vascular or lymphatic circulation, penetrate the target tissue and proliferate and metastasize subsequently. Fully potent malignant invasive cell phenotypes are fully equipped to negotiate all steps in the sequence. However, failure in any of these steps will result in loss of metastatic behavior and elimination of the tumor cells. Very small percentage of cell which reaches to circulation will survive and form metastases, which may be attributed to the development of competency for every step of the cascade independently, in a random and reversible fashion.\[12\]

Further, it is now evident by the work of Kerbel et al.\[13\] that the subpopulation of cells capable to metastasize dominate in the primary tumor mass early in its growth. In extension to these findings, the studies of Cornil et al.\[14\] and Kerbel\[15\] have shown that factors that behaved as growth inhibitors in early stages of benign tumors can transform as mitogens when tumor cells attain metastatic competence. These metastatically competent cells are therefore responsible for clonal dominance even at distant metastatic foci.

The steps in metastasis formation necessitate specific interactions with the ECM like decreased adhesiveness to the tumor or stromal matrix. Tumor-specific patterns of metastasis formation may be guided by specific tumor endothelial interactions and selective binding to specific matrix components.\[16,17\] The tumor cells also respond differently to various extracellular matrices and stromal cells that are encountered during metastasis formation. The concept of dynamic reciprocity\[18\] (normal cells that produce ECM are also influenced by that matrix) in normal cells is also valid for tumor cells and the extracellular matrices that they encounter. However, the responses of malignant tumor cells to various matrix components deviate from the normal cells.\[19\] The behavior of malignant tumor cell with the ECM is characterized by its tendency to cross tissue boundaries, intermix with cells of the various compartments and metastasize to distant sites,\[19\] and this may be the resultant of loss of control over the expression of the invasive phenotype observed in these normal cells.\[20\]

The acquisition of invasive phenotype by a cell is better understood by studying tumor cell interaction with the basement membrane, as the breach in basement membrane is defined as the critical event of tumor invasion, that signals the initiation of the metastatic cascade.\[12,20\] This event is not a simple process, as basement membrane puts forward connective tissue barriers at multiple key points in the metastatic cascade. These basement membranes are composed of a dense meshwork of collagen Type IV, laminin and heparan sulfate proteoglycans and do not contain pores that would allow passive tumor cell migration. The ability of cell to traverse basement membrane barriers is defined by acquisition of an invasive phenotype which is governed by three steps, i.e., attachment, local proteolysis and migration. Furthermore, these three steps describe tumor cell interaction with all extracellular matrices and not restricted to basement membranes. The nature of the specific interaction (i.e., tumor cell types and type of matrix) may result in selection of certain steps over others at particular points in the metastatic cascade. Thus, establishment of successful metastatic ability of cell is brought through the repetitive cycling of these three
Metastasis is therefore a multistep process, defined by the invasive phenotype that is dominated by the ability of tumor cells to attach to the ECM, to degrade matrix components and then migrate through these matrix defects. However, these functions is not unique to tumor cell behavior but also be found in normal cells. An understanding of the factors that control cellular processes essentially pertaining to the malignant invasive phenotype will open up research area for identification of new biomarkers of ECM for early detection, therapeutic targets for prevention and metastasis.

**MEDIATORS OF CELL TO EXTRACELLULAR MATRIX INTERACTIONS**

Cell adhesion and invasion in malignancy is through a number of specific cell surface-associated molecules which mediate cell to ECM and intercellular interactions. These include the integrins, 67 kD laminin-binding protein, cadherins, Ig superfamily and CD44. The tumor cells for effective metastatic process should demonstrate decreased cell and matrix adhesive properties at various stages of the metastatic cascade. Hence, apparent contribution of each class of cell adhesion molecules to the net cellular and matrix adhesiveness of tumor cells will be dependent on a variety of factors inducing the metastatic capacity of the tumor cell population under study and the model system used to study these cells.

Integrins are a family of cell surface receptors that mediate cell adhesion. The integrins were originally identified as receptors for ECM proteins such as collagens, fibronectin, laminin and vitronectin. Some integrins may also function as cell-cell adhesion molecules. Integrins adhere to more than one ligand, and ligands can be recognized by more than one integrin. Integrins bind through recognition of the RGD sequence common to a number of adhesive molecules including fibronectin, vitronectin and other adhesion proteins. Integrin-mediated signaling pathways control cell growth, differentiation, apoptosis, cytoskeletal changes, cell migration and invasion. The cell migration and invasion depends not only on integrin expression levels but also on ligand-binding affinity. Studies as that of Albelda et al. and Gehlsen et al. have demonstrated increased vitronectin receptor in malignant melanoma cells. The major integrin receptors are also been described in OSCC which include α2 β1, α3 β1, α5 β1 and α6 β4. Therefore, changes in ECM composition and integrin profiles can have profound effects on OSCC development and progression.

Laminin is the most important noncollagenic protein matrix in the basal membrane identified by Chung et al. However, Timpl et al. isolated the first isoform of laminin from murine Engelbreth-Holm-Swarm sarcoma and characterized it as a major noncollagenous basement membrane glycoprotein of molecular weight 850,000–1,000,000 consisting of two major types of polypeptide chains in a ratio 1:2 held together by disulfide bonds. Laminin, a basement membrane-associated glycoprotein, distributed exclusively on the epithelial portion of basement membrane in the lamina lucida, is chemically and immunologically distinct and functions as an adhesive glycoprotein-binding epithelial cell to Type IV collagen and basement membrane.

The study conducted by Firth and Reade showed that laminin and collagen IV distribution were continuous in epithelial hyperplasia while dysplastic lesions showed small focal breaks whose number increased in severe dysplasias. Kannan et al. reported a gradual increase in the frequency of laminin and collagen IV discontinuity from normal epithelium to hyperplastic, dysplastic and squamous cell carcinomas. Harada et al. found that the staining pattern of laminin and collagen IV in primary OSCC was similar to that of metastatic nodules and observed that cellular population of the deep areas expressed the invasive and metastatic potential of oral carcinoma. These findings of Harada et al. may be attributed to development of tumors from the cells which are normally associated with basal lamina production. The basement membrane component like laminin and Type IV collagen produced around the tumor cells may be resultant of differentiated phenotype of the tumor cells.

Laminin isoform – Ln-5 is extensively explored in OSCC. Ln-5 has dual function which can promote adhesion and migration. This dual function of Ln-5 is determined by proteolytic processing which determines whether Ln-5 is an adhesive factor or a migratory factor. Loss of Ln-5 expression has been demonstrated in OSCC, which favors the binding of other ligands such as collagen or fibronectin that may be more conducive to tumor growth. The unoccupied Ln-5 receptors can also bind laminin isoforms that stimulate tumor growth, like Ln-10/11 which binds to the same integrin receptors as Ln-5, has been shown to stimulate keratinocyte proliferation. However, several studies have indicated that Ln-5 is also overexpressed in OSCC contributing for tumor development and progression. Ln-5 expression has also been described along the invasive edge of OSCC to correlate a poor prognosis in patients with OSCC. Recent studies, have now indicated that Ln-5 expression at the invasive front of OSCC is primarily, a means to retard tumor invasion in OSCC.
The cadherins are a family of homophilic cell adhesion proteins expressed in a variety of tissues which require Ca++ binding for adhesiveness, rigidity and stability. Three subtypes (E-, N- and P-cadherins) have been identified in mammals and are primarily distinguished on the basis of tissue distribution. Epithelial cadherin also termed as E cadherin or cadherin 1 is a transmembrane glycoprotein, functioning as a cell adhesion molecule. Calcium-dependent adhesion proteins (cadherins) play a critical role in cell adhesion and tissue differentiation. Dysfunctional E cadherin is associated with loss of differentiation and acquisition of invasive phenotype.

E cadherin acts a tumor suppressor and found to be lost during carcinogenesis. This loss of expression of E-cadherin may be attributed to impairment in intercellular association, demarcating the possible initiation of the procarcinogenic process in this epithelial layer. Loss of E-cadherin expression has a negative impact on cellular adhesiveness, the process of cellular differentiation and cellular polarity in the epithelium that induces the cells to attain a migratory phenotype, a significant feature associated with malignant transformation. There are several mechanisms that have been proposed regarding the loss of E-cadherin. First, Palacios et al. who suggested that Src-dependent endocytosis of E-cadherin followed by its degradation which becomes upregulated during cancer invasion leads to the loss of membranous E-cadherin and accumulation of the same in cytoplasm of dysplastic epithelial cells. This cytoplasmic accumulation of the E-cadherin is known to be associated with deregulated transport of cytoplasmic E-cadherin – β-catenin complex to the cell membrane as well as enhanced recycling of E-cadherin by endocytosis which eventually undergoes ubiquitination which may thus lead to irreversible alteration in epithelial structural integrity through the loss of E-cadherin. Second, Alvarado et al. has suggested two plausible reasons of E-cadherin loss from proliferative layers: (1) the proteolytic cleavage of its ectodomain by MMP-7 which may cause enhanced cytoplasmic accumulation and (2) loss or reduction of E-cadherin expression from the proliferative layer can be caused by somatic mutations, chromosomal deletions, proteolytic cleavage and silencing of the CDH1 promoter which can occur either by DNA hypermethylation or through the action of transcription factors such as Slug, Snail and Twist.

CD44, a transmembrane glycoprotein, known to act as a receptor for hyaluronan can bind to ECM ligands such as chondroitin sulfate, heparan sulfate, fibronectin, serglycin and osteopontin with lower affinity. Numerous variant isoforms of CD44 are derived as a result of alternate splicing leading to combinations of exons which are inserted into the extracellular domain of proliferating epithelial cells and activated lymphocytes. CD44 plays a vital role in lymphocyte homing. Alternative splicing and glycosylation influence receptor function of the CD44 molecule and thereby reduces the affinity toward hyaluronan. The cytoplasmic domain of CD44 networks itself cytoskeletal through ankryn and proteins belonging to the ezrin-moesin-radixin family. Studies on CD44 have correlated pattern of CD44 variants produced by neoplastic cells and clinicopathological parameters of tumors, such as grade, stage, presence of metastases and survival in carcinomas of the digestive tract, non-Hodgkin’s lymphomas and thyroid carcinomas. The different ligand recognition by CD44 can influence cell motility, invasive properties and metastatic potential of tumors.

Collagens are also found in association with oral epithelium. Type I collagen shows an active role in malignant transformation of epithelial cells and often expressed with well-differentiated OSCC. However, such an active role of collagen IV in malignancy remains obscure, as collagen IV reduced or loss of expression can be correlated to decrease tumor cell differentiation and at other times collagen IV increased expression may lead to nodal metastasis. A study using microarray expression profiling has demonstrated increased expression of collagen IV in OSCC. Mutations in collagen Type VII is known to cause epidermal squamous cell carcinoma in association with dystrophic epidermolysis bullosa. These evidentiary findings although indicate changes in collagen expression promote adhesion, migration and differentiation. The precise mechanism should be further explored before confirming whether loss or overexpression of collagen isoform is a common prerequisite for OSCC tumor invasion.

PROTEOLYSIS IN INVASION

Proteolysis and migration through tissue barriers are noted in normal cell functions under specific physiologic circumstances. However, the terms of malignant neoplasia define a shift toward sustained invasive capacity. The invasion is guided by a cyclic attachment to and subsequent release of matrix components in a programmed manner. This implies that enhanced proteolysis in tumor cells is still tightly regulated in a temporal and spatial fashion with respect to cell attachment and migration. The association of proteases with the invasive process is through inappropriate overexpression in the malignant tissue, either by the tumor cells, host cells intermixed or immediately adjacent to the invasion front or both. This overexpression mechanics holds good for all the classes of proteases: thiol-, seryl-asparyl and metallo-proteases. The difference between enzyme
production under physiologic and neoplastic conditions may be that in tumor cells, the enzymes may be regulated by autocrine growth factor stimulation. Tumor cells become unresponsive to signals that would down-regulate MMP expression from host cells and matrix. Activation of proenzyme is an important control point for the development of the invasive phenotype, which occurs in the presence of tissue inhibitors of MMP (TIMPs), the endogenous and ubiquitous TIMPs. The balance between active enzyme and TIMP decides the process local matrix degradation occurs. Overexpression of MMP proenzymes and subsequent activation is the mechanism by which tumor cells achieve a balance in favor of proteolysis. Proteolysis activity is always at a constant check between the local concentration of activated enzymes and their endogenous inhibitors.\(^7\)

Evidence for the role of MMP enzymes in tumor invasion and metastasis comes from in vitro studies from murine and human tumor cells lines that transcribe, synthesize and secrete MMP enzymes.\(^78\),\(^79\) The ECM components, cell-matrix interactions and the pericellular environment all act as determinants of MMP production. There exists studies that correlate MMP expression with invasive behaviour, and metastatic potential in animal models\(^80\)–\(^82\) and also studies that demonstrate modulation of these MMP expression by growth factors.\(^83\)–\(^85\) OSCC cells not only produce many of the ECM proteins but also synthesize and secrete MMPs. ECM components found in the oral epithelium are proteolytically processed. The processing of ECM molecules results in the liberation of peptides, and such peptides are termed as "matrikine." Matrikines affect various cellular activities such as proliferation, migration, apoptosis and angiogenesis.\(^86\) Several matrikines are generated during proteolytic processing of the Ln-5 precursor. Matrikines generated from the \(\alpha 3\) and \(\beta 3\) chains of the Ln-5 precursor chains promote migration,\(^87\),\(^88\) and N-terminal \(\gamma 2\) chain proteolytic fragments of Ln-5 precursor is detected in patients with pancreatic ductal cell adenocarcinoma.\(^89\) Further, \(\gamma 2\) chain of Ln-5 precursor and its proteolytic fragments have been found at the invasive fronts of OSCC.\(^89\)

Several collagen-derived matrikines also have been reported. The tripeptide glycyl-L-histidyl-L-lysine present in the \(\alpha 2\) chain of Type I collagen has demonstrated angiogenesis in vitro.\(^90\) stimulate ECM synthesis and increase the expression of MMP-2. Another matrikine produced by C-terminal domain, of the \(\alpha 3\) chain of Type IV collagen, decreases tumor cell proliferation and migration.\(^91\) Further, Endostatin (a C-terminal domain of Type XVIII collagen) has demonstrated antiangiogenic properties, and therefore, OSCC which expresses collagen Type XVIII fails to exhibit nodal metastasis.\(^91\) However, the role of matrikines in development and progression of oral cancer requires further exploration.

**CONCLUSION**

ECM not only acts as a support of epithelial tissues but also acts as a network for regulating transcriptional controls and cell signaling mechanisms that are involved in cell adhesion, migration, tumor development and progression. It is also noted that the proteases and proteases inhibitor balance operates wisely in ECM and thereby influencing cell-matrix interactions which favours proteolytic cleavage of ECM a step a prerequisite for invasion and migration. Understanding the role of ECM in tumor development, invasion and migration may open up new insights in early detection, preventive and treatment strategies for oral cancer.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Ferlay J, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base (2002 Estimates). Lyon: IARC Press, 2004.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45.
3. Khan Z. An overview of oral cancer in Indian subcontinent and recommendations to decrease its incidence. Webmedcentral Cancer 2012;2:WMC003626.
4. Chaturvedi AK, Anderson WF, Lorret-Tiexile J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013;31:4550-9.
5. Meltzer A, Dormancy and breast cancer. J Surg Oncol 1990;43:181-8.
6. Zajicek G. Long survival with micrometastases. At least 9% of breast cancer patients carry metastases for more than 10 years. Cancer J 1987;1:414-5.
7. Bosman FT. Integrins: Cell adhesives and modulators of cell function. Histochem J 1993;25:469-77.
8. Colognato H, Yurchenco PD. Form and function: The laminin family of heterotrimers. Dev Dyn 2000;218:213-34.
9. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol 2004;20:255-84.
10. Kikkawa Y, Sanzen N, Fujisawa H, Sonnenberg A, Sekiguchi K. Integrin binding specificity of laminin-10/11: Laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. J Cell Sci 2000;113 (Pt 5):869-76.
11. Rousselle P, Aumailley M. Kalinin is more efficient than laminin in cell-matrix interactions which favours proteolytic cleavage of ECM a step a prerequisite for invasion and migration. Understanding the role of ECM in tumor development, invasion and migration may open up new insights in early detection, preventive and treatment strategies for oral cancer.
12. Bosman FT. Integrins: Cell adhesives and modulators of cell function. Histochem J 1993;25:469-77.
13. Colognato H, Yurchenco PD. Form and function: The laminin family of heterotrimers. Dev Dyn 2000;218:213-34.
14. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annu Rev Cell Dev Biol 2004;20:255-84.
15. Kikkawa Y, Sanzen N, Fujisawa H, Sonnenberg A, Sekiguchi K. Integrin binding specificity of laminin-10/11: Laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. J Cell Sci 2000;113 (Pt 5):869-76.
16. Rousselle P, Aumailley M. Kalinin is more efficient than laminin in cell-matrix interactions which favours proteolytic cleavage of ECM a step a prerequisite for invasion and migration. Understanding the role of ECM in tumor development, invasion and migration may open up new insights in early detection, preventive and treatment strategies for oral cancer.
Kumar and Hema: Extracellular matrix contribution in invasion and metastasis

14. Cornil J, Theodorescu D, Man S, Herlyn M, Jambrosie J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A 1991;88:6028-32.

15. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. Am J Pathol 1992;141:519-24.

16. Pauli BU, Augustin-Yoss HG, el-Sabban ME, Johnson RC, Hammer DA. Organ-prefecture of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Rev 1990;9:175-89.

17. Zhu DZ, Cheng CF, Pauli BU. Mediation of lung metastasis of murine melanomas by a lung-specific endothelial cell adhesion molecule. Proc Natl Acad Sci U S A 1991;88:9568-72.

18. Sage EH, Bornstein P. Extracellular proteins that modulate cell-matrix interactions. SPARC, tenasin, and thrombospondin. J Biol Chem 1991;266:14831-4.

19. Mareel MM, Van Roy FM, De Baetselier P. The invasive phenotypes. Cancer Metastasis Rev 1990;9:45-62.

20. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-36.

21. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993;68:4-17.

22. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science 1987;238:491-7.

23. Yamada KM. Adhesive recognition sequences. J Biol Chem 1991;266:12809-12.

24. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.

25. Ziobor BI, Silverman SS Jr., Kramer RH. Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 2001;12:499-510.

26. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Kerbel RS. The invasive phenotypes. Cancer Metastasis Rev 1990;9:175-89.

27. Ziober BL, Silverman SS Jr., Kramer RH. Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 2001;12:499-510.

28. Chung AE, Freeman IL, Braginski JE. A novel extracellular membrane protein elaborated by a mouse embryonal carcinoma-derived cell line. Biochem Biophys Res Commun 1977;79:859-68. Wewer UM, Engvall E. Laminin – A glycoprotein from basement membranes. J Biol Chem 1980;22:719-26.

29. Cornil J, Theodorescu D, Man S, Herlyn M, Jambrosie J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A 1991;88:6028-32.

30. Murray JC, Stingl G, Kleinman HK, Martin GR, Katz SI. Epidermal cells adhere preferentially to type IV (basement membrane) collagen. J Cell Biol 1979;80:197-202.

31. Terranova VP, Rohrbach DH, Martin GR. Role of laminin in the attachment of PAM 212 (epithelial) cells to basement membrane collagen. Cell 1980;22:719-26.

32. Firth NA, Reade PC. The prognosis of the oral mucosal squamous cell carcinomas: A comparison of clinical and histopathological grading and of laminin and type IV collagen staining. Aust Dent J 1996;41:85-98. Wewer UM, Engvall E. Laminin – A glycoprotein from basement membranes. J Biol Chem 1980;22:719-26.

33. Kannan S, Balamurugan P, Chandran GJ, Pillai MR, Mathew B, Nalinakumari KR, et al. Alterations in expression of basement membrane proteins during tumour progression in oral mucosa. Histopathology 1994;24:531-7.

34. Harada T, Shinohara M, Nakamura S, Oka M. An immunohistochemical study of the extracellular matrix in oral squamous cell carcinoma and its association with invasive and metastatic potential. Virchows Arch 1994;424:257-66.

35. Barsky SH, Siggel GP, Jannotta F, Liotta LA. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983;49:140-7.

36. Goldfinger LE, Hopkinson SB, deHart GW, Collman S, Couchman JR, Jones JC. The alpha3 laminin subunit, alpha3beta4 and alpha3beta1 integrin coordinately regulate wound healing in cultured epithelial cells and in the skin. J Cell Sci 1999;112 (Pt 16):2615-29.

37. Lohi J. Laminin-5 in the progression of carcinomas. Int J Cancer 2001;94:763-7.

38. Gagnon-Palacios L, Allegre M, Spiritio F, Pommereau O, Romero C, Ortonne JP, et al. The short arm of the laminin gamma2 chain plays a pivotal role in the incorporation of laminin 5 into the extracellular matrix and in cell adhesion. J Cell Biol 2001;153:835-50.

39. McGowan K, Veitch D, Findell P, Russell A, Ho WB, Marinovich MP. Bmp-1 Processing of Laminin-5 Controls Migration of Human Epithelial Cells. Annual Meeting of the Society of Investigative Dermatology, 2000.

40. Clark EA, King WG, Bragg JS, Symons M, Hynes RO. Integrin-mediated signals regulated by members of the rho family of GTPases. J Cell Biol 1998;142:573-86.

41. Thorup AK, Reibel J, Schiodt M, Stenersen TC, Therkildsen MH, Carter WG, et al. Can alterations in integrin and laminin-5 expression be used as markers of malignancy? JAPMIS 1998;106:1170-80.

42. Ferletta M, Ekblom P. Identification of laminin-10/11 as a strong cell adhesive complex for a normal and a malignant human epithelial cell line. J Cell Sci 1999;112 (Pt 1):1-8.

43. Pouliot N, Saunders NA, Kaur P. Laminin 10/11: An alternative adhesive ligand for epidermal keratinocytes with a functional role in promoting proliferation and migration. Exp Dermatol 2002;11:387-97.

44. Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, et al. The gamma 2 chain of Kelvinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 1994;145:782-91.

45. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995;55:4132-9.

46. Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S, et al. Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res 1999;59:5596-601.

47. Skyldberg B, Salo S, Eriksson E, Aspenblad U, Moberger B, Tryggvason K, et al. Laminin-5 as a marker of invasiveness in cervical lesions. J Natl Cancer Inst 1999;91:1882-7.

48. Lenander C, Habermann JK, Ost A, Nilsson B, Schimmelpenning H, Tryggvason K, et al. Laminin-5 gamma 2 chain expression correlates with unfavorable prognosis in colon carcinomas. Anal Cell Pathol 2001;22:201-9.

49. Ono Y, Nakashiyi Y, Ino Y, Niki T, Yamada T, Yoshimura K, et al. Clinopathologic significance of laminin-5 gamma2 chain expression in squamous cell carcinoma of the tongue: Immunohistochemical analysis of 67 lesions. Cancer 1999;85:2315-21.

50. Katoh K, Nakashiyi Y, Akimoto S, Yoshimura K, Takagi M, Sakamoto M, et al. Correlation between laminin-5 gamma2 chain expression and epidermal growth factor receptor expression and its clinicopathological significance in squamous cell carcinoma of the tongue. Oncology 2002;62:318-26.

51. Ono Y, Nakashiyi Y, Gotoh M, Sakamoto M, Hirohashi S. Epidermal growth factor receptor gene amplification is correlated with laminin-5 gamma2 chain expression in oral squamous cell carcinoma cell lines. Cancer Lett 2002;175:197-204.

52. Nakayama M, Sato Y, Okamoto M, Hirohashi S. Increased expression of laminin-5 and its prognostic significance in hypopharyngeal cancer. Laryngoscope 2004;114:4129-33.
55. Gianmelli G, Milillo I, Marinocci F, Lo Muzio L, Serpico R, Antonaci S. Altered expression of integrins and basement membrane proteins in malignant and pre-malignant lesions of oral mucosa. J Biol Regul Homeost Agents 2001;15:375-80.

56. von Zeidler SV, de Souza Botelho T, Mendonça EF, Batista AC. E-cadherin as a potential biomarker of malignant transformation in oral leukoplakia: A retrospective cohort study. BMC Cancer 2014;14:972.

57. Wong TS, Gao W, Chan JY. Interactions between E-cadherin and microRNA deregulation in head and neck cancers: The potential interplay. Biomed Res Int 2014;2014:126038.

58. Das RK, Pal M, Barui A, Paul RR, Chakraborty C, Ray AK, et al. Assessment of malignant potential of oral submucous fibrosis through evaluation of p63, E-cadherin and CD105 expression. J Clin Pathol 2010;63:894-9.

59. Fresko D, Lazarus SS. Oral carcinoma in situ. Its progression to squamous, basosquamous, and basal-cell carcinoma. Arch Pathol Lab Med 1981;105:15-9.

60. Larue L, Antos C, Busz S, Huber O, Delmas V, Dominis M, et al. A role for cathepsins in tissue formation. Development 1996;122:3185-94.

61. Downer CS, Speight PM. E-cadherin expression in normal, hyperplastic and malignant oral epithelium. Eur J Cancer B Oral Oncol 1993;29B:303-5.

62. Palacios F, Tushir JS, Fujita Y, D’Souza-Schorey C. Lysosomal targeting of cell surface glycoproteins. J Cell Biol 1990;111:2765-74.

63. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303‑13.

64. Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS, et al. Multifactorial regulation of E-cadherin expression: An integrative study. Mol Cancer Ther 2010;9:1-6.

65. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-13.

66. Alvarado CG, Maruyama S, Cheng J, Iida-Yonemochi H, Kobayashi T, Yamazaki M, et al. Nuclear translocation of β-catenin synchronized with loss of E-cadherin in oral epithelial dysplasia with a characteristic two-phase appearance. Histopathology 2011;59:283-91.

67. Culty M, Miyake K, Kincade PW, Sikorski E, Butcher EC, Underhill C. A role for cathepsins in tissue formation. Development 1996;122:3185-94.

68. Sreenath T, Matrisian LM, Steetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 1992;52:4942-7.

69. Brown PD, Levy AT, Margulis IM, Liotta LA, Steetler-Stevenson WG. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. J Biol Chem 1993;268:8148-91.

70. Ogata Y, Pratta MA, Nagase H, Arner EC. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) is induced in rabbit articular chondrocytes by cotreatment with interleukin 1 beta and a protein kinase C activator. Exp Cell Res 1992;201:245-9.

71. Weinberg WC, Brown PD, Steetler-Stevenson WG, Yuspa SH. Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation 1990;45:168-78.

72. Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the interplay. Biomed Res Int 2014;2014:126038.

73. Tsubota Y, Mizushima H, Hirosaki T, Higashi S, Yasumitsu H, Miyazaki K. Isolation and activity of proteolytic fragment of laminin-5 alpha3 chain. Biochem Biophys Res Commun 2000;278:614-9.

74. Hintermann E, Quaranta V. Epithelial cell motility on laminin-5: Regulation by matrix assembly, proteolysis, integrins and erbB receptors. Matrix Biol 2004;23:75-85.

75. Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst 1998;90:1890-8.

76. Nakajima M, Welch DR, Belloni PN, Nicolson GL. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987;47:4869-76.

77. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 1993;9:541-73.

78. Lyons JG, Birkedal-Hansen B, Moore WG, O’Grady RL, Birkedal-Hansen H. Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. Biochemistry 1991;30:1449-56.

79. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992;7:77-83.

80. Bonfil RD, Reddel RR, Ura H, Reich R, Fridman R, Harris CC, et al. Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst 1989;81:587-94.

81. Powell WC, Knox JD, Navre M, Grogan TM, Kettelson J, Nagle RB, et al. Expression of the metalloproteinase matrixin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993;53:417-22.

82. Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the interplay. Biomed Res Int 2014;2014:126038.

83. Birkedal-Hansen B, Moore WG, O’Grady RL, Birkedal-Hansen H. Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. Biochemistry 1991;30:1449-56.

84. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992;7:77-83.

85. Bonfil RD, Reddel RR, Ura H, Reich R, Fridman R, Harris CC, et al. Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line. J Natl Cancer Inst 1989;81:587-94.

86. Powell WC, Knox JD, Navre M, Grogan TM, Kettelson J, Nagle RB, et al. Expression of the metalloproteinase matrixin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993;53:417-22.

87. Sreenath T, Matrisian LM, Steetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 1992;52:4942-7.

88. Brown PD, Levy AT, Margulis IM, Liotta LA, Steetler-Stevenson WG. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. J Biol Chem 1993;268:8148-91.

89. Ogata Y, Pratta MA, Nagase H, Arner EC. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) is induced in rabbit articular chondrocytes by cotreatment with interleukin 1 beta and a protein kinase C activator. Exp Cell Res 1992;201:245-9.

90. Weinberg WC, Brown PD, Steetler-Stevenson WG, Yuspa SH. Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation 1990;45:168-78.

91. Maquart FX, Bellon G, Pasco S, Monboisse JC. Matrikines in the interplay. Biomed Res Int 2014;2014:126038.

92. Birkedal-Hansen B, Moore WG, O’Grady RL, Birkedal-Hansen H. Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. Biochemistry 1991;30:1449-56.